Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Other Operating Expenses (2023)

Prime Medicine (PRME) has disclosed Other Operating Expenses for 3 consecutive years, with $13.5 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Other Operating Expenses changed N/A year-over-year to $13.5 million, compared with a TTM value of $13.5 million through Sep 2024, down 82.11%, and an annual FY2023 reading of $13.5 million, changed N/A over the prior year.
  • Other Operating Expenses was $13.5 million for Q4 2023 at Prime Medicine, down from $40.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $40.9 million in Q3 2023 and bottomed at $3.0 million in Q3 2021.
  • Average Other Operating Expenses over 3 years is $22.7 million, with a median of $22.0 million recorded in 2022.
  • The sharpest move saw Other Operating Expenses surged 727.45% in 2022, then skyrocketed 63.16% in 2023.
  • Year by year, Other Operating Expenses stood at $3.0 million in 2021, then soared by 727.45% to $25.0 million in 2022, then plummeted by 46.1% to $13.5 million in 2023.
  • Business Quant data shows Other Operating Expenses for PRME at $13.5 million in Q4 2023, $40.9 million in Q3 2023, and $34.6 million in Q2 2023.